Epirus Biopharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014
For the nine months, the company reported loss from operations of $29,100,000 against $10,637,000 a year ago. Loss before income taxes was $31,427,000 against $13,038,000 a year ago. Net loss was $31,445,000 against $13,022,000 a year ago. Basic and diluted loss per share was $8.15 against $55.38 a year ago.